Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christopher Baggett"'
Autor:
Bradford Jackson, Stephanie Wheeler, Juan Yanguela, Matthew LeBlanc, Tzy-Mey Kuo, Christopher Baggett, Katherine Reeder-Hayes
Publikováno v:
Cancer Research. 83:P1-06
BACKGROUND: The impact of treatment delays on cancer outcomes has been well documented, but few published studies explicitly attempt to identify subgroups which would benefit the most from potential interventions improving timeliness of care. Using t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6317f47cc0a730a3ab6ef9b3d89b2340
https://doi.org/10.1158/1538-7445.sabcs22-p1-06-04
https://doi.org/10.1158/1538-7445.sabcs22-p1-06-04
Autor:
Jessica Yasmine Islam, Xi Zhou, Christopher Baggett, Christine Jamjian, Anna E. Coghill, Gita Suneja, Jennifer L. Lund
Publikováno v:
Cancer Research. 83:745-745
Background: People living with HIV (PLWH) are less likely to receive any cancer treatment, however, reasons for this disparity are unclear. One factor may be oncologists’ concerns regarding potential drug-drug interactions (DDIs) between cancer and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::357d369e439d1e00690bd4600914a622
https://doi.org/10.1158/1538-7445.am2023-745
https://doi.org/10.1158/1538-7445.am2023-745
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S175-S176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2c2081c01a7acf8eae5f06e66b6f938
https://doi.org/10.1016/s2152-2650(22)00584-5
https://doi.org/10.1016/s2152-2650(22)00584-5
Autor:
Daniel R. Richardson, Xi Zhou, Christopher Edward Jensen, Katherine Elizabeth Reeder-Hayes, Jennifer Leigh Lund, Christopher Baggett
Publikováno v:
Journal of Clinical Oncology. 40:6586-6586
6586 Background: Older adults with acute myeloid leukemia (AML) have identified time at home (TAH) as a critical outcome when deciding on treatment. No study to date has fully explored TAH for older adults with AML. Methods: We identified a cohort of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::340c94b4649522dee4c9323c15861b41
https://doi.org/10.1200/jco.2022.40.16_suppl.6586
https://doi.org/10.1200/jco.2022.40.16_suppl.6586
Autor:
Hannah Elizabeth Dzimitrowicz, Lauren E. Wilson, Bradford E. Jackson, Lisa Spees, Christopher Baggett, Melissa A. Greiner, Deborah Kaye, Tian Zhang, Daniel J. George, Charles D. Scales, Jessica Pritchard, Michael S. Leapman, Cary Philip Gross, Michaela Ann Dinan, Stephanie B. Wheeler
Publikováno v:
Journal of Clinical Oncology. 40:300-300
300 Background: Although oral anti-cancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC), most patients still die from the disease. High quality end-of-life (EOL) care remains a crucial component of opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69cad5f1757dd030c8e3c68678ea74e3
https://doi.org/10.1200/jco.2022.40.6_suppl.300
https://doi.org/10.1200/jco.2022.40.6_suppl.300